RELMADA THERAPEUTICS INC
RLMDNASDAQ🏆 #3108 by market capEarnings Nov 5US Equity
$3.44▲ $0.09 (+2.69%)
🌅 Pre-market$3.31▼ 3.78%Regular close · extended-hours price shownTrack RLMD
Get earnings, price moves & breaking news on Telegram
24h▲ 2.7%
7d▲ 5.5%
14d▲ 10.6%
30d▼ 8.6%
ytd▼ 28.7%
1y▲ 48.9%
🏦Market Cap
$367M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
RELMADA THERAPEUTICS INC
RLMDAnalyst Ratings
Price
$3.44
Total
8
Raised
1
Lowered
3
Avg PT
$12.00
H / L
$12 / $12
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Mizuho | Reiterated | Outperform | 2026-03-20 | — | — |
Leerink Partners | Upgraded | Market Perform → Outperform | 2026-01-23 | $8.00 | +132.60% |
Goldman Sachs | Downgraded | Neutral → Sell | 2024-06-05 | $2.00 | −41.90% |
SVB Leerink | Reiterated | Outperform | 2023-01-23 | — | — |
Guggenheim | Downgraded | Buy → Neutral | 2022-10-14 | — | — |
Oppenheimer | Downgraded | Outperform → Perform | 2022-10-13 | $7.00 | +103.50% |
SunTrust Robinson Humphrey | Reiterated | Buy | 2020-11-25 | — | — |
Jefferies | Reiterated | Buy | 2020-11-25 | $9.00 | +161.60% |
Institution
Mizuho
Reiterated · Outperform · 2026-03-20
—
—
Leerink Partners
Upgraded · Market Perform → Outperform · 2026-01-23
$8.00
+132.60%
Goldman Sachs
Downgraded · Neutral → Sell · 2024-06-05
$2.00
−41.90%
SVB Leerink
Reiterated · Outperform · 2023-01-23
—
—
Guggenheim
Downgraded · Buy → Neutral · 2022-10-14
—
—
Oppenheimer
Downgraded · Outperform → Perform · 2022-10-13
$7.00
+103.50%
SunTrust Robinson Humphrey
Reiterated · Buy · 2020-11-25
—
—
Jefferies
Reiterated · Buy · 2020-11-25
$9.00
+161.60%
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space